New Hope for Neuro care: Lupin Opens “Atharv” An Advanced Ability Center in Delhi

Date:

Share post:

Lupin has inaugurated Atharv Ability, an advanced multidisciplinary neuro-rehabilitation center in Delhi, marking a significant step toward strengthening specialized neurological care in India. The facility is designed to provide integrated rehabilitation services for patients recovering from neurological disorders, injuries, and disabilities through a patient-centric and technology-enabled approach.

Atharv Ability brings together experts across neurology, physiotherapy, occupational therapy, speech therapy, psychology, and rehabilitation medicine under one roof, aiming to support holistic recovery and improve quality of life for patients. The center is expected to cater to individuals affected by conditions such as stroke, spinal cord injuries, Parkinson’s disease, cerebral palsy, and traumatic brain injuries.

With the launch of this center, Lupin continues to expand its healthcare footprint beyond pharmaceuticals, focusing on accessible and comprehensive patient care. The initiative reflects the growing importance of multidisciplinary rehabilitation services in addressing India’s rising neurological healthcare needs.

By Sharon Bose & Arundhuti Chatterjee

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related articles

Dabur India Plant Under US FDA Scanner Over Contamination Concerns

The United States Food and Drug Administration (US FDA) has flagged serious concerns at Dabur India's manufacturing facility...

FDA Approves Wockhardt’s Novel Antibiotic ZAYNICH™️ for cUTI

Wockhardt Limited  announced that the U.S. Food and Drug Administration (FDA) has approved ZAYNICH™ (cefepimeand zidebactam), a novel intravenous antibiotic...

Relief for Patients: NPPA Fixes Ceiling Prices for 30 Essential Medicines

The National Pharmaceutical Pricing Authority (NPPA) has notified ceiling prices for 30 essential fixed-dose combination medicines under the...

FDA Draft Guidance Aims to Reduce Animal Testing for Cancer Drugs

The U.S. Food and Drug Administration (FDA) issued a new draft guidance aimed at reducing unnecessary animal testing...